Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
NCT05366218Phase 2Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Mar 2023
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab in acute lymphoblastic leukemia (ALL), sponsored by University Hospital Tübingen. Primary endpoints: Safety and Maximum Tolerated Dose (Part I) at 49 days and Time until hematological relapse or increase of MRD (Part II) at 545 days. Started Mar 2023; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05366218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366218.